Global Intravenous Iron Drugs Market Size study & Forecast, by Product (Iron Sucrose, Iron Dextran, Ferric Carboxymaltose, Others), by Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others) and Regional Analysis, 2023-2030

Global Intravenous Iron Drugs Market Size study & Forecast, by Product (Iron Sucrose, Iron Dextran, Ferric Carboxymaltose, Others), by Application (Chronic Kidney Disease, Inflammatory Bowel Disease, Cancer, Others) and Regional Analysis, 2023-2030

Global Intravenous Iron Drugs Market is valued at approximately USD 2.92 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.6% over the forecast period 2023-2030. Intravenous iron drugs are medications administered directly into the bloodstream to replenish iron stores in the body. They are used when oral iron supplements are ineffective or not suitable. These drugs help treat iron deficiency anemia by rapidly increasing iron levels in the body. The rising prevalence of chronic kidney disease, inflammatory bowel disease, and cancer, which are important indications for intravenous iron usage, is a significant driver for market growth. Additionally, the growing incidence of infectious diseases such as malaria, HIV/AIDS, TB, hepatitis, pneumonia, and influenza is expected to increase the demand for intravenous drugs in the future.

Moreover, the growing prevalence of cancer can support the growth of the Intravenous Iron Drugs Market. According to the WHO in 2022, Cancer, responsible for nearly 10 million deaths in 2020, remains a prominent global cause of mortality. In terms of new cases of cancer in 2020, the following were the most prevalent: Breast cancer accounted for 2.26 million cases, followed by lung cancer with 2.21 million cases, colon and rectum cancer with 1.93 million cases, prostate cancer with 1.41 million cases, non-melanoma skin cancer with 1.20 million cases, and stomach cancer with 1.09 million cases in 2020. Additionally, an growing investment in drugs development is anticipated to create the lucrative opportunity for the market during forecast period. However, adverse reactions associated with intravenous iron drugs stifling market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Intravenous Iron Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing prevalence of chronic kidney disease, gastrointestinal illnesses, and cancers in the region. Asia Pacific is expected to grow at fastest growth rate during the forecast period, owing to supportive government initiatives and the development of healthcare infrastructure. In addition, the high incidence of chronic kidney disease in developing nations such as China and India have aided market growth.

Major market player included in this report are:
CSL Limited
Covis Pharma GmbH
Daiichi Sankyo Company, Ltd.
Sanofi S.A.
Pharma cosmos A/S
Shield Therapeutics Plc
AbbVie Inc.
Rockwell Medical Inc
Americal Reagent Inc
Pfizer Inc.

Recent Developments in the Market:
In November 2022, Fer inject an intravenous iron therapy, obtained approval from China's National Medical Products Administration (NMPA). This approval allows CSL Vifor and Fresenius Kabi to utilize Fer inject for treating iron deficiency in adult patients who are unresponsive to oral iron preparations, unable to use them, or require rapid iron delivery due to clinical necessity.

In November 2022, a group of researchers funded by the National Institutes of Health (NIH) initiated a study to investigate the effectiveness of intravenous iron drug treatment for women with post-pregnancy anemia. The study aims to enrol approximately 5,000 women across multiple countries, including India, Bangladesh, Pakistan, the Democratic Republic of Congo, Kenya, Zambia, and Guatemala.

Global Intravenous Iron Drugs Market Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered - Product, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Product:
Iron Sucrose
Iron Dextran
Ferric Carboxymaltose
Others
By Application:
Chronic Kidney Disease
Inflammatory Bowel Disease
Cancer
Others
By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
CSL Limited
Covis Pharma GmbH
Daiichi Sankyo Company, Ltd.
Sanofi S.A.
Pharma cosmos A/S
Shield Therapeutics Plc
AbbVie Inc.
Rockwell Medical Inc
Americal Reagent Inc
Pfizer Inc.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.